| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-10 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.23 | 3e-10 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.31 | 2e-09 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-09 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-09 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-09 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.21 | 7e-09 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-08 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-08 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-07 |